How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

Viking Therapeutics' obesity drug candidate VK2735 could potentially grow a $1,000 investment to $2,500-$3,400 by 2030 under favorable conditions, but faces significant competition from established players Eli Lilly and Novo Nordisk. The company will likely need to dilute shares through fundraising, and the drug must capture at least 1% market share to justify current valuations. Clinical trial failure could reduce investments by 60-80%.